modelCholinesterase
Extends from Pharmacolibrary.Drugs.ATC.V.V03AB29.
Information
| name: | Cholinesterase | |
| ATC code: | V03AB29 | route: |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Cholinesterase is an enzyme that catalyzes the hydrolysis of acetylcholine and other choline esters. As a drug term, 'cholinesterase' typically refers to treatments involving exogenous administration of the enzyme as a detoxifying or antidotal agent in cases of organophosphate or carbamate poisoning. It is not a medication used in routine therapy and does not have broad clinical use currently. The ATC code V03AB29 refers to preparations of cholinesterase used as antidotes.
Pharmacokinetics
No published pharmacokinetic parameters for exogenously administered cholinesterase in humans were identified; values are unreported and not estimable from existing literature.
References
Gomolin, IH, et al., & Jeitner, TM (2011). Cholinesterase inhibitors: applying pharmacokinetics to clinical decision making. The American journal of geriatric pharmacotherapy 9(4) 259–263. DOI:10.1016/j.amjopharm.2011.06.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21763214
Defilippi, JL, & Crismon, ML (2003). Drug interactions with cholinesterase inhibitors. Drugs & aging 20(6) 437–444. DOI:10.2165/00002512-200320060-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12710863
Farlow, MR (2003). Clinical pharmacokinetics of galantamine. Clinical pharmacokinetics 42(15) 1383–1392. DOI:10.2165/00003088-200342150-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14674789
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)